Donate For Public and Patients Store Search

C022 - Advanced Self-assessment of Dermatopathology

Monday, March 4; 9:00 AM - 4:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Diagnose complex skin conditions more effectively
  • Recognize conditions to be included in the differential diagnosis of challenging dermatopathology cases.
  • Select special stains and immunohistochemistries that may be required to reach the diagnosis.

Description

This session is mostly dedicated to practitioners who read dermatopathology and dermatopathology fellows. In the morning (9-12 noon), 50 virtual slides will be provided with a short clinical history per case. The cases will be individually reviewed by the participants and a multiple choice questionnaire filled. In the afternoon the faculty will discuss the morphological features and differential diagnosis of each case providing important clues to the audience to help reach the most appropriate diagnosis. Additional special stains or immunohistochemistries to confirm the diagnosis will also be shown when appropriate. This activity has been approved by the American Board of Dermatology (ABD) for up to 50 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org.

Disclosures

  • Ferringer, Tammie C., MD: no financial relationships exist with commercial interests.
  • Guitart, Joan, MD: Actelion – I(Grants/Research Funding); Elorac, Inc. – I(Grants/Research Funding); Galderma Research & Development, LLC – I(Grants/Research Funding); LEO Laboratories Ltd (LEO Pharma) – A(Fees); miRagen Therapeutics, Inc. – I(Grants/Research Funding); Soligenix, Inc – I(Grants/Research Funding);
  • High, Whitney A., MD, JD: no financial relationships exist with commercial interests.
  • Junkins-Hopkins, Jacqueline M., MD: no financial relationships exist with commercial interests.
  • Piliang, Melissa, MD: Eli Lilly and Company – I(NC); Pfizer Inc. – I(NC); Procter & Gamble Company – C(H);
  • Robinson-Bostom, Leslie, MD: no financial relationships exist with commercial interests.
  • Sangueza, Omar P., MD: no financial relationships exist with commercial interests.
  • Tetzlaff, Michael, MD, PhD: Myriad Genetics Inc – A(Fees); Novartis – A(Fees); Seattle Genetics – C(Fees);
  • Thompson, Curtis T., MD: no financial relationships exist with commercial interests.
  • Vandergriff, Travis W., MD: no financial relationships exist with commercial interests.
Schedule
Monday, March 4
1:00 PM
Dr. Guitart / Case 1-5
1:15 PM
Dr. High / Case 6-10
1:30 PM
Dr. Junkins-Hopkins / Cases 11-15
1:55 PM
Dr. Piliang / Cases 16-20
2:10 PM
Dr. Robinson-Bostom / Cases 21-25
2:25 PM
Dr. Sangueza / Case 26-30
2:50 PM
Dr. Tetzlaff / Cases 31-35
3:05 PM
Dr. Thompson / Cases 36-40
3:20 PM
Dr. Vandergriff / Cases 41-45
3:35 PM
Dr. Ferringer / Cases 46-50
Event Details
  • Date
    Monday, March 4
  • Time
    9:00 AM - 4:00 PM
  • Location
    Room 151B
  • CME Credits
    6.00
  • Type
    Ticketed
    MOC
Directors/Co-Directors
  • Joan Guitart, MD, FAAD
Speakers